IBDEI1S0 ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,31744,2)
 ;;=^5001930
 ;;^UTILITY(U,$J,358.3,31745,0)
 ;;=D05.10^^190^1943^88
 ;;^UTILITY(U,$J,358.3,31745,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31745,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Unspec Breast
 ;;^UTILITY(U,$J,358.3,31745,1,4,0)
 ;;=4^D05.10
 ;;^UTILITY(U,$J,358.3,31745,2)
 ;;=^5001929
 ;;^UTILITY(U,$J,358.3,31746,0)
 ;;=D50.0^^190^1943^89
 ;;^UTILITY(U,$J,358.3,31746,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31746,1,3,0)
 ;;=3^Iron Deficiency Anemia Secondary to Blood Loss
 ;;^UTILITY(U,$J,358.3,31746,1,4,0)
 ;;=4^D50.0
 ;;^UTILITY(U,$J,358.3,31746,2)
 ;;=^267971
 ;;^UTILITY(U,$J,358.3,31747,0)
 ;;=D50.9^^190^1943^90
 ;;^UTILITY(U,$J,358.3,31747,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31747,1,3,0)
 ;;=3^Iron Deficiency Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,31747,1,4,0)
 ;;=4^D50.9
 ;;^UTILITY(U,$J,358.3,31747,2)
 ;;=^5002283
 ;;^UTILITY(U,$J,358.3,31748,0)
 ;;=C46.9^^190^1943^91
 ;;^UTILITY(U,$J,358.3,31748,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31748,1,3,0)
 ;;=3^Kaposi's Sarcoma,Unspec
 ;;^UTILITY(U,$J,358.3,31748,1,4,0)
 ;;=4^C46.9
 ;;^UTILITY(U,$J,358.3,31748,2)
 ;;=^5001108
 ;;^UTILITY(U,$J,358.3,31749,0)
 ;;=C22.0^^190^1943^92
 ;;^UTILITY(U,$J,358.3,31749,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31749,1,3,0)
 ;;=3^Liver Cell Carcinoma
 ;;^UTILITY(U,$J,358.3,31749,1,4,0)
 ;;=4^C22.0
 ;;^UTILITY(U,$J,358.3,31749,2)
 ;;=^5000933
 ;;^UTILITY(U,$J,358.3,31750,0)
 ;;=D05.02^^190^1943^93
 ;;^UTILITY(U,$J,358.3,31750,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31750,1,3,0)
 ;;=3^Lobular Carcinoma in Situ,Left Breast
 ;;^UTILITY(U,$J,358.3,31750,1,4,0)
 ;;=4^D05.02
 ;;^UTILITY(U,$J,358.3,31750,2)
 ;;=^5001928
 ;;^UTILITY(U,$J,358.3,31751,0)
 ;;=D05.01^^190^1943^94
 ;;^UTILITY(U,$J,358.3,31751,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31751,1,3,0)
 ;;=3^Lobular Carcinoma in Situ,Right Breast
 ;;^UTILITY(U,$J,358.3,31751,1,4,0)
 ;;=4^D05.01
 ;;^UTILITY(U,$J,358.3,31751,2)
 ;;=^5001927
 ;;^UTILITY(U,$J,358.3,31752,0)
 ;;=D05.00^^190^1943^95
 ;;^UTILITY(U,$J,358.3,31752,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31752,1,3,0)
 ;;=3^Lobular Carcinoma in Situ,Unspec Breast
 ;;^UTILITY(U,$J,358.3,31752,1,4,0)
 ;;=4^D05.00
 ;;^UTILITY(U,$J,358.3,31752,2)
 ;;=^5001926
 ;;^UTILITY(U,$J,358.3,31753,0)
 ;;=R59.0^^190^1943^56
 ;;^UTILITY(U,$J,358.3,31753,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31753,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Localized
 ;;^UTILITY(U,$J,358.3,31753,1,4,0)
 ;;=4^R59.0
 ;;^UTILITY(U,$J,358.3,31753,2)
 ;;=^5019529
 ;;^UTILITY(U,$J,358.3,31754,0)
 ;;=C83.59^^190^1943^96
 ;;^UTILITY(U,$J,358.3,31754,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31754,1,3,0)
 ;;=3^Lymphoblastic Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,31754,1,4,0)
 ;;=4^C83.59
 ;;^UTILITY(U,$J,358.3,31754,2)
 ;;=^5001590
 ;;^UTILITY(U,$J,358.3,31755,0)
 ;;=C83.50^^190^1943^97
 ;;^UTILITY(U,$J,358.3,31755,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31755,1,3,0)
 ;;=3^Lymphoblastic Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,31755,1,4,0)
 ;;=4^C83.50
 ;;^UTILITY(U,$J,358.3,31755,2)
 ;;=^5001581
 ;;^UTILITY(U,$J,358.3,31756,0)
 ;;=C43.9^^190^1943^99
 ;;^UTILITY(U,$J,358.3,31756,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31756,1,3,0)
 ;;=3^Malig Melanoma of Skin,Unspec
 ;;^UTILITY(U,$J,358.3,31756,1,4,0)
 ;;=4^C43.9
 ;;^UTILITY(U,$J,358.3,31756,2)
 ;;=^5001015
 ;;^UTILITY(U,$J,358.3,31757,0)
 ;;=C31.9^^190^1943^100
 ;;^UTILITY(U,$J,358.3,31757,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31757,1,3,0)
 ;;=3^Malig Neop Accessory Sinus,Unspec
